Psycheceutical Bioscience has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic...
Psyence Group has confirmed that it has exported purified pharmaceutical-grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (CDMO) partner in the UK.
Peter Reitano, CEO of Gwella, speaks to Psychedelic Health about the company’s mission to provide education on psychedelics and raise acceptance of the compounds beyond mental...
Field Trip Health & Wellness has launched Field Trip Online Therapy for people seeking therapeutic support and for people looking to integrate insights and learnings from...
Irwin Naturals has signed a Letter of Intent entering into a partnership with Braxia Scientific – which is developing innovative ketamine and psilocybin treatments for mental...
Algernon Pharmaceuticals (AGN Pharma) has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance its DMT stroke programme.
With psychedelics and psychedelic-assisted psychotherapy showing promise as potential treatments for mental health conditions, skilled facilitators who can provide therapy for patients and in clinical trials...
The Psychedelics as Medicine Report has revealed the industry is currently worth US$650 million (~£542 million), and is expected to exceed US$3 billion by 2026.
Psychedelics venture studio Nucleus has raised USD$135,000 from investors through its Wefunder campaign.
Former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, has been appointed to the role of Executive Special Advisor by Clearmind Medicine.
